Physician profile
Asad U Qamar
NPI 1033145487
$6,063.25
in general payments reported to CMS, 2019-2025
26 companies · $971 in 2025
The $971 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $327 · 2021: $733 · 2022: $726 · 2023: $1,283 · 2024: $1,708 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,961.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,233.87 | 2021-2025 | Turbohawk, Corevalve Evolut R, Abre |
| Abbott Laboratories | $1,150.89 | 2023-2025 | Aveir, Jot Dx, Coroflow |
| Lundbeck LLC | $567.80 | 2019-2021 | |
| Biotronik INC. | $411.49 | 2019-2024 | Biomonitor, Orsiro Mission |
| Pfizer INC. | $330.67 | 2022-2023 | |
| Amgen INC. | $321.36 | 2019-2025 | Tepezza, Repatha |
| Janssen Pharmaceuticals, INC | $318.96 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $314.41 | 2021-2025 | Opticross 35, Peripheral Rotalink Plus, Ranger |
| Vasorum USA INC. | $232.19 | 2022-2025 | Celt Acd |
| Impulse Dynamics (USA) INC. | $164.26 | 2023-2025 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $155.33 | 2024-2025 | Camzyos |
| W. L. Gore & Associates, INC. | $143.39 | 2022-2024 | Gore Viabahn Endoprosthesis With Heparin, Gore Viabahn Vbx Balloon Expandable Endo |
| Philips North America LLC | $140.33 | 2021-2024 | (P84) Igt Devices Systems |
| Merck Sharp & Dohme LLC | $123.54 | 2021-2022 | |
| Insulet Corporation | $101.74 | 2025 | Omnipod |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $69.00 | 2020-2023 | Brilinta |
| Novartis Pharmaceuticals Corporation | $65.68 | 2019-2024 | |
| Novo Nordisk INC | $59.46 | 2021-2023 | Ozempic |
| Baxter Healthcare | $27.53 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Organogenesis INC. | $25.44 | 2021 | |
| Cordis US Corp. | $24.40 | 2025 | Mynx Control |
| Cashflow Solutions, LLC | $20.47 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Medtronic Vascular, INC. | $20.27 | 2020 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Inspire Medical Systems, INC. | $14.60 | 2024 | Inspire |
| Astellas Pharma US INC | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,000,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Qamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.